Empagliflozin
Empagliflozin (sodium-glucose cotransporter 2 inhibitor)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Jardiance, BI 10773, SGLT2 inhibitor
Four randomised outcome trials in more than 23,000 people, including a 32 percent relative reduction in all-cause death in EMPA-REG OUTCOME. The entire ageing case is one single-laboratory mouse study reporting 5.9 percent longer median survival in males, and the Interventions Testing Program has never tested this drug.
Overview
Empagliflozin blocks the kidney transporter that reabsorbs filtered glucose, so glucose and the sodium travelling with it leave in the urine. It was licensed as a diabetes drug and then turned out to do something its mechanism did not obviously predict, which is reduce cardiovascular death, heart failure hospitalisation and kidney disease progression, including in people without diabetes.
Those trials are among the largest and cleanest in modern cardiology. EMPA-REG OUTCOME randomised 7,020 people with type 2 diabetes at high cardiovascular risk and reported death from any cause in 5.7 percent on empagliflozin against 8.3 percent on placebo. EMPEROR-Reduced randomised 3,730 people with heart failure and an ejection fraction of 40 percent or less. EMPEROR-Preserved randomised 5,988 with an ejection fraction above 40 percent. EMPA-KIDNEY randomised 6,609 people with chronic kidney disease.
None of those trials measured ageing. They measured death, hospitalisation and kidney function decline in sick people over a median of 2.0 to 3.1 years.
The geroscience claim rests on something much smaller. A 2024 study from a single laboratory in Chongqing reported that empagliflozin extended median survival of naturally aged male mice by 5.9 percent, improved learning, memory and motor balance, and reduced markers of liver senescence. That is one cohort, one site, one strain, one sex reported for the survival number.
Mechanism of action
Selectively inhibits sodium-glucose cotransporter 2 in the proximal tubule, so filtered glucose is excreted rather than reabsorbed. The cardiorenal benefit is larger and faster than glucose lowering alone explains and is not fully accounted for. Candidate contributions include reduced plasma volume and preload, restored tubuloglomerular feedback and lower intraglomerular pressure, a shift toward ketone utilisation by the myocardium, and reduced cardiac sodium-hydrogen exchange. The mouse healthspan work adds AMPK and SIRT1 signalling, short-chain fatty acid production and gut microbial composition to that list, which is a different level of evidence from the outcome trials.
Human evidence
Extensive and high quality for cardiorenal and metabolic disease, and completely absent for ageing. More than 23,000 people have been randomised in the four trials above and none of them measured a geroscience endpoint.
- EMPA-REG OUTCOME, 7,020 randomised: all-cause death 5.7 percent against 8.3 percent on placebo over a median 3.1 years, in people with type 2 diabetes and established cardiovascular disease.
- EMPEROR-Reduced, 3,730 randomised: cardiovascular death or heart failure hospitalisation 19.4 percent against 24.7 percent, benefit present with and without diabetes.
- EMPEROR-Preserved, 5,988 randomised: same composite 13.8 percent against 17.1 percent, driven mainly by hospitalisations rather than deaths.
- EMPA-KIDNEY, 6,609 randomised: kidney progression or cardiovascular death 13.1 percent against 16.9 percent, but all-cause death 4.5 percent against 5.1 percent was not significant.
- No randomised trial has measured lifespan, healthspan, biological age, frailty or any ageing endpoint with empagliflozin in any population.
What this does not tell you: Every participant above had diabetes, heart failure or chronic kidney disease. The absolute benefit in those trials comes from preventing events that a healthy 45 year old is not at meaningful risk of having in the next three years. Nothing in this dataset describes what the drug does to a metabolically healthy person taking it for decades, and the known harms, genital mycotic infection, volume depletion and euglycaemic ketoacidosis, do not shrink in a lower-risk population.
Reading the research record
There are two separate evidence questions about any repurposed drug and they have different answers. The first is whether the drug does what it was licensed to do, which here is settled by randomised trials with hard clinical endpoints. The second is whether it slows ageing in humans, which no trial has tested. The strength of the first answer says nothing about the second. A reader who takes the licensed indication as partial proof of the ageing claim has made the central error of this field.
The attribution problem is specific and worth stating plainly. The National Institute on Aging Interventions Testing Program, which runs genetically heterogeneous UM-HET3 mice at three independent sites and publishes its nulls, has tested canagliflozin. It reported a 14 percent extension of median male survival and a 9 percent increase in the age at 90th percentile survival, with no effect in females, and it has since run a late-start canagliflozin cohort. It has not tested empagliflozin. Searching the literature for the programme and this drug together returns nothing.
The empagliflozin lifespan claim comes from a 2024 single-laboratory study in naturally aged mice that reported a 5.9 percent gain in median male survival. That is a smaller effect, from one site, with none of the design features that make the Interventions Testing Program results worth their reputation. Coverage that says an SGLT2 inhibitor extends lifespan in the NIA programme and then illustrates it with empagliflozin has merged two different compounds and two very different tiers of evidence.
The authors of the canagliflozin paper offer an interpretation worth carrying over: they attribute the lifespan benefit to blunting peak glucose, on the grounds that acarbose produces a similar male-preferential effect through an entirely different mechanism. If that is right, the relevant variable is postprandial glucose control rather than any particular molecule, and the SGLT2 class has no special claim.
The evidence, charted
Fig. 1 · evidence composition
4of 6 citations (67%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 5 distinct years, 2015 to 2024, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Human2015
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
EMPA-REG OUTCOME. 7,020 people with type 2 diabetes at high cardiovascular risk, median observation 3.1 years. The primary composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke occurred in 10.5 percent on empagliflozin against 12.1 percent on placebo (hazard ratio 0.86, P = 0.04). Death from any cause was 5.7 percent against 8.3 percent, a 32 percent relative risk reduction. There was no significant difference in rates of myocardial infarction or stroke, and genital infection was more common on the drug.
New England Journal of Medicine - Human2020
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
EMPEROR-Reduced. 3,730 people with class II to IV heart failure and an ejection fraction of 40 percent or less, median 16 months. Cardiovascular death or heart failure hospitalisation occurred in 19.4 percent against 24.7 percent on placebo (hazard ratio 0.75). Estimated glomerular filtration rate fell by 0.55 against 2.28 ml per minute per 1.73 square metres per year. The effect held regardless of diabetes status.
New England Journal of Medicine - Human2021
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
EMPEROR-Preserved. 5,988 people with class II to IV heart failure and an ejection fraction above 40 percent, median 26.2 months. Cardiovascular death or heart failure hospitalisation occurred in 13.8 percent against 17.1 percent (hazard ratio 0.79). The authors state the effect was mainly driven by fewer heart failure hospitalisations rather than fewer deaths.
New England Journal of Medicine - Human2023
Empagliflozin in Patients with Chronic Kidney Disease
EMPA-KIDNEY. 6,609 people with chronic kidney disease, median 2.0 years. Kidney disease progression or cardiovascular death occurred in 13.1 percent against 16.9 percent (hazard ratio 0.72). Notably for anyone reading the drug as a mortality intervention, death from any cause was 4.5 percent against 5.1 percent and was not a significant difference in this trial.
New England Journal of Medicine - Animal2024
Empagliflozin rescues lifespan and liver senescence in naturally aged mice
The entire mouse lifespan case, from one laboratory. Empagliflozin extended the median survival of male mice by 5.9 percent, improved learning, memory and motor balance, lowered body weight, reduced hepatic P21 and P16, altered gut flora composition and raised short-chain fatty acids. A single-site study, not part of any multi-site replication programme.
GeroScience - Animal2020
Canagliflozin extends life span in genetically heterogeneous male but not female mice
This is the Interventions Testing Program SGLT2 result, and it is canagliflozin, not empagliflozin. Canagliflozin at 180 ppm in chow from 7 months of age extended median male survival by 14 percent and raised the 90th percentile survival age by 9 percent, with parallel effects at all three test sites. No lifespan benefit in females. Attributing this result to empagliflozin is a factual error that circulates widely.
JCI Insight
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Genital mycotic infection is the most consistently reported effect and is a documented trial finding rather than anecdote, in both sexes and more often in women.
- Increased urination, thirst and mild volume depletion are near universal early reports, with orthostatic symptoms described by people who were already on diuretics.
- Weight loss of a few kilograms is commonly described and is expected from urinary calorie loss rather than from any ageing mechanism.
- Euglycaemic diabetic ketoacidosis is the serious one, and community discussion repeatedly underestimates it because blood glucose looks normal while it is happening. Fasting, low carbohydrate intake, acute illness and surgery all raise the risk, and a glucometer will not warn you.
Sources: Longevity forums, diabetes communities and clinic write-ups. Uncontrolled self-report, useful for knowing what to watch for and worthless as evidence of an ageing effect.
Frequently asked questions
Does empagliflozin extend lifespan?
In one single-laboratory study in naturally aged mice, median male survival was 5.9 percent longer. There is no human lifespan or healthspan evidence of any kind. The large human trials measured cardiovascular death, heart failure hospitalisation and kidney decline in people who already had those diseases.
Did the Interventions Testing Program test empagliflozin?
No. The programme tested canagliflozin, which extended median male survival by 14 percent with no effect in females, and it has run a late-start canagliflozin cohort since. A literature search for the programme and empagliflozin together returns nothing. The two drugs are frequently confused in longevity coverage.
The trials showed a 32 percent reduction in death. Is that not a longevity result?
It is a mortality result in people with type 2 diabetes and established cardiovascular disease, over roughly three years. Preventing cardiovascular death in high-risk patients is not the same as slowing ageing, and EMPA-KIDNEY, in a different population, found no significant difference in all-cause death at all.
Is it safe to take while fasting?
This is the specific combination to be careful about. SGLT2 inhibitors can produce ketoacidosis at a normal-looking blood glucose, so a fingerstick reading gives no warning, and a planned fast is the same metabolic exposure as the pre-surgical window for which stopping the drug is advised. That is a conversation with a prescriber, not a forum.
How does it compare with metformin or acarbose for ageing?
All three are glucose-lowering drugs with strong records in their licensed indication and no human ageing data. Acarbose and canagliflozin both produced male-preferential lifespan extension in the multi-site mouse programme. Metformin did not. Empagliflozin has not been run in that programme at all.